Trials / Completed
CompletedNCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib | |
| DRUG | MEDI4736 |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2015-03-27
- Last updated
- 2019-06-27
- Results posted
- 2019-06-27
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02401048. Inclusion in this directory is not an endorsement.